AMLX
Amylyx Pharmaceuticals, Inc.- Healthcare
- Biotechnology
- $3.52B market cap
Forecast run · Sep 14, 2026Upside rank 82 of 3,136
Model Signal
ForecastQ Daily Probabilities
75.8%
43.5%
42.3%
Analyst Consensus
Recommendation2.09/5 Buy
Last price$31.62
Price target$52.20
Implied move+65.1%
Analysts11
ForecastQ Portfolios
AMLX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.